# Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2020 · $152,199

## Abstract

ABSTRACT
In sub-Saharan Africa and globally, many persons who inject drugs (PWID) are living with undiagnosed or
untreated HIV, experience high levels of poverty, food and housing instability, and discrimination, and have
increased risk for health conditions that contribute to worse outcomes from COVID-19. It is also more challenging
for PWID to access healthcare when services have been limited by lockdowns and measures to ensure social
distancing to prevent spread of respiratory viruses, such as SARS-CoV-2. We propose to recruit and follow a
cohort of 500 HIV-positive and 500 HIV-negative PWID and their partners, many of whom also have hepatitis C,
to determine whether poorly controlled HIV infection, active drug use and other HIV- and PWID-specific risk
factors result in increased likelihood of COVID-19 acquisition, viral transmission, symptomatic disease and
poor clinical outcomes (AIM 1). We will also define transmission dynamics through phylogenetic analyses
of SAR-CoV-2 sequences from symptomatic PWID (AIM 2) and determine whether HIV care and harm
reduction service delivery disruptions are associated with poor compliance to ART and methadone, HIV
viremia and other adverse outcomes (AIM 3). Our proposal is innovative in how it reaches PWID and partners
using peer educators, employs targeted testing and symptom screening in this high-risk Kenyan population, and
defines COVID-19 transmission within and beyond local networks using phylogenetics. Participant recruitment
and enrollment will take place in drop-in centers and methadone clinics in Nairobi, Mombasa and Kilifi, Kenya
and follow-up visits will occur monthly for 6 months. In addition to collecting interview data and blood for SARS-
CoV-2 antibodies, we will ask participants who have symptoms consistent with COVID-19 at any of the 7 visits
to self-collect a nasal swab specimen for SARS-CoV-2 polymerase chain reaction (PCR), followed by genome
sequencing if positive. Laboratory assays for antibody and viral PCR testing will be conducted in Nairobi and
positive specimens will be shipped to Seattle for sequencing and phylogenetic analysis. We anticipate that our
results will highlight the need for targeted testing among PWID and inform interventions and programs for HIV
and addiction care and treatment across the globe for similar marginalized populations when confronted with
COVID-19 and other public health crises.

## Key facts

- **NIH application ID:** 10208545
- **Project number:** 3R01DA043409-04S2
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** CAREY FARQUHAR
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $152,199
- **Award type:** 3
- **Project period:** 2017-05-15 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10208545

## Citation

> US National Institutes of Health, RePORTER application 10208545, Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention (3R01DA043409-04S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10208545. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*